In CRC clinical practice, the status of KRAS and NRAS (NRAS proto-oncogene, GTPase) mutations serves as a predictive biomarker to anti-EGFR therapy, but is only applicable in the metastatic setting [62]. Here, KRAS is linked to colorectal carcinoma.